Werewolf Therapeutics Inc Cash Flow-to-Debt Ratio
Werewolf Therapeutics Inc cash flow-to-debt ratio. Werewolf Therapeutics Inc (HOWL) has a Cash Flow-to-Debt Ratio of 0.84x as of June 2026, meaning its operating cash flow of $6.63 Million could theoretically repay 1% of its total liabilities ($7.86 Million) in one year. Check HOWL cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Werewolf Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of Werewolf Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for Werewolf Therapeutics Inc across 7 annual periods. Check how aggressively does Werewolf Therapeutics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Werewolf Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Werewolf Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Werewolf Therapeutics Inc. For the full cash flow conversion analysis, see Werewolf Therapeutics Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.35x | $-60.29 Million | $44.59 Million | ▼ -28.8% |
| 2024 | -1.05x | $-56.19 Million | $53.54 Million | ▼ -104.2% |
| 2023 | -0.51x | $-32.61 Million | $63.46 Million | ▲ +52.0% |
| 2022 | -1.07x | $-40.60 Million | $37.91 Million | ▲ +33.9% |
| 2021 | -1.62x | $-42.88 Million | $26.46 Million | ▲ +37.5% |
| 2020 | -2.59x | $-18.62 Million | $7.18 Million | ▼ -223.8% |
| 2019 | -0.80x | $-9.54 Million | $11.91 Million | — |